Skip to content

Prevention of Fetal Alcohol Spectrum Disorder (FASD) by the Use of Technology

Prevention of Fetal Alcohol Spectrum Disorder (FASD) by the Use of Technology

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02759874
Enrollment
110
Registered
2016-05-03
Start date
2015-11-30
Completion date
2018-11-30
Last updated
2017-09-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alcoholism, Pregnancy

Brief summary

The Institute of Health Economics is conducting a study to determine how a breathalyzer linked to a cloud based alcohol monitoring system changes alcohol consumption during pregnancy in women with alcohol dependency issues. IHE posits that the ability to self-monitor blood alcohol concentration and the ability to share sobriety via email or text with loved ones and counselors may reduce alcohol consumption and thus reduce the possibility of delivering a child with FASD. The study will provide useful evidence for tailoring future optimal maternal and child healthcare for women, with the potential of decreasing healthcare utilization by prevention of FASD. Breathalyzer device usage plus secure document sobriety should improve patient monitoring convenience and demonstrate reductions in alcohol use outside of traditional office visits and patient self-reports.

Interventions

DEVICEspecialized breathalyzer w face recognition technology

Sponsors

University of Alberta
CollaboratorOTHER
SoberLink, LLC
CollaboratorINDUSTRY
Alberta Innovates Health Solutions
CollaboratorOTHER
Alberta Health services
CollaboratorOTHER
Institute of Health Economics, Canada
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Pregnant, Alcoholic, actively in treatment for alcoholism addiction

Exclusion criteria

* Not pregnant, not in treatment/therapy for addiction

Design outcomes

Primary

MeasureTime frameDescription
Change in FASD Birthrate Levels3 yearsBinary- yes or no dx FASD within 3 years of birth

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026